Hyaluronidase - Halozyme

Drug Profile

Hyaluronidase - Halozyme

Alternative Names: Hyaluronidase human injection - Halozyme; Hylenex; HYLENEX® recombinant; rHuPH20

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Halozyme Therapeutics
  • Developer Avid Bioservices
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Enzyme modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Unspecified

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 07 Mar 2007 Clinical data added to the pharmacokinetics section
  • 14 Feb 2007 Baxter Healthcare expanded their agreement with Halozyme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top